Observational studyDisease markers2017
Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients.
Observational study in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Nomogram-based risk assessment model for left ventricular hypertrophy in patients with essential hypertension: Incorporating clinical characteristics and biomarkers.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy.ESC heart failure · 2023Article
- IL-33/ST2 pathway as upper-hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure.ESC heart failure · 2022Review
- Changes in Left Heart Geometry, Function, and Blood Serum Biomarkers in Patients with Obstructive Sleep Apnea after Treatment with Continuous Positive Airway Pressure.Medicina (Kaunas, Lithuania) · 2022Article
- Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure.Frontiers in cardiovascular medicine · 2022Article
- Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases.Frontiers in cardiovascular medicine · 2022Review
- Biomarker profiling for risk of future heart failure (HFpEF) development.Journal of translational medicine · 2021Article
- Human Immunodeficiency Virus-Associated Myocardial Diastolic Dysfunction and Soluble ST2 Concentration in Tanzanian Adults: A Cross-Sectional Study.The Journal of infectious diseases · 2021Article
- Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Article
- Blood microRNA 202-3p associates with the risk of essential hypertension by targeting soluble ST2.Bioscience reports · 2020Article
- Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients.Disease markers · 2020Observational
- Are soluble ST2 levels influenced by vitamin D and/or the seasons?Endocrine connections · 2019Article
- Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction.Disease markers · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEchocardiographic evaluation of left ventricular (LV) structural and functional alterations in hypertension has some limitations, potentially overcome by using biomarkers. ST2, a prognostic biomarker for heart failure and myocardial infarction patients, was less studied in hypertension.
aimTo analyze the relationship between serum ST2 levels and diastolic dysfunction (DD) in hypertension.
methodWe enrolled 88 hypertensive outpatients (average age 65 years, 69.3% females) in a prospective study, stratified for presence of LV hypertrophy (LVH). For each patient clinical examination, lab workup (routine and serum ST2 levels) and echocardiography were performed.
resultsHypertensive patients with LVH had higher age, pulse pressure, mean arterial pressure, and serum ST2, while having lower serum albumin than those without LVH. Serum ST2 levels correlate with parameters of LV remodeling and DD. We found that 5.3% of ST2 level variability was caused by a 1-unit variation of cardiovascular risk. We identified cut-off values for discriminating hypertension with LVH versus that without LVH and grade 2 DD versus normal diastolic performance.
conclusionST2 could be used as diagnostic biomarker for cardiac remodeling and altered diastolic performance in hypertension, providing additional data to echocardiography. It could represent a milestone in early detection of cardiac performance alteration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.